Patent: 5,843,439
✉ Email this page to a colleague
Summary for Patent: 5,843,439
Title: | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
Abstract: | Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies. |
Inventor(s): | Anderson; Darrell R. (Escondido, CA), Hanna; Nabil (Olivenhain, CA), Leonard; John E. (Encinitas, CA), Newman; Roland A. (San Diego, CA), Reff; Mitchell E. (San Diego, CA), Rastetter; William H. (Rancho Sante Fe, CA) |
Assignee: | |
Application Number: | 08/478,967 |
Patent Claims: | see list of patent claims |
Details for Patent 5,843,439
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Acrotech Biopharma Llc | ZEVALIN | ibritumomab tiuxetan | Injection | 125019 | 02/19/2002 | ⤷ Try a Trial | 2015-12-01 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 5,843,439
Country | Patent Number | Estimated Expiration |
---|---|---|
South Africa | 938466 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 9411026 | ⤷ Try a Trial |
United States of America | 7744877 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |